The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Bio-Rad Laboratories's revenues will increase 3.8% and EPS will contract -2.8%.
The average estimate for revenue is $504.6 million. On the bottom line, the average EPS estimate is $1.06.
Last quarter, Bio-Rad Laboratories chalked up revenue of $573.8 million. GAAP reported sales were 4.3% higher than the prior-year quarter's $550.2 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $1.55. GAAP EPS of $1.46 for Q4 were 30% lower than the prior-year quarter's $2.08 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 54.7%, 180 basis points worse than the prior-year quarter. Operating margin was 8.6%, 700 basis points worse than the prior-year quarter. Net margin was 7.3%, 350 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $2.15 billion. The average EPS estimate is $5.36.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 178 members out of 187 rating the stock outperform, and nine members rating it underperform. Among 50 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 48 give Bio-Rad Laboratories a green thumbs-up, and two give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Bio-Rad Laboratories is outperform, with an average price target of $112.25.
Looking for alternatives to Bio-Rad Laboratories? It takes more than great companies to build a fortune for the future. Learn the basic financial habits of millionaires next door and get focused stock ideas in our free report, "3 Stocks That Will Help You Retire Rich." Click here for instant access to this free report.
- Add Bio-Rad Laboratories to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
It's Showtime for Bio-Rad Laboratories
Don't Get Too Worked Up Over Bio-Rad Laboratories's Earnings
Don't just count the cash, time it.
Something Worth Watching at Bio-Rad Laboratories
Look here for a clue.